All Stories

  1. Mesalazine-induced nephrolitiasis and crystalluria
  2. Desarrollo de actividades para el aprendizaje de la fisiología mediante creación de contenido para redes sociales
  3. Estimated Phytate Intake Is Associated with Bone Mineral Density in Mediterranean Postmenopausal Women
  4. Association between coffee consumption and total dietary caffeine intake with cognitive functioning: cross-sectional assessment in an elderly Mediterranean population
  5. Cross-sectional association between non-soy legume consumption, serum uric acid and hyperuricemia: the PREDIMED-Plus study
  6. Association of Adherence to The Mediterranean Diet with Urinary Factors Favoring Renal Lithiasis: Cross-Sectional Study of Overweight Individuals with Metabolic Syndrome
  7. Dietary inflammatory index and all-cause mortality in large cohorts: The SUN and PREDIMED studies
  8. Cohort Profile: Design and methods of the PREDIMED-Plus randomized trial
  9. Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial
  10. Effect of Consumption of Cocoa-Derived Products on Uric Acid Crystallization in Urine of Healthy Volunteers
  11. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts
  12. Mediterranean diet and quality of life: Baseline cross-sectional analysis of the PREDIMED-PLUS trial
  13. Potato Consumption Does Not Increase Blood Pressure or Incident Hypertension in 2 Cohorts of Spanish Adults
  14. Prediction of Cardiovascular Disease by the Framingham‐REGICOR Equation in the High‐Risk PREDIMED Cohort: Impact of the Mediterranean Diet Across Different Risk Strata
  15. Legume consumption is inversely associated with type 2 diabetes incidence in adults: A prospective assessment from the PREDIMED study
  16. Dietary α‐Linolenic Acid, Marine ω‐3 Fatty Acids, and Mortality in a Population With High Fish Consumption: Findings From the PREvención con DIeta MEDiterránea (PREDIMED) Study
  17. Dietary fat intake and risk of cardiovascular disease and mortality
  18. Mediterranean Diet, Retinopathy, Nephropathy, and Microvascular Diabetes Complications: A Post Hoc Analysis of a Randomized Trial
  19. Effect of consuming a grape seed supplement with abundant phenolic compounds on the oxidative status of healthy human volunteers
  20. Relationship between Urinary Level of Phytate and Valvular Calcification in an Elderly Population: A Cross-Sectional Study
  21. Benefits of the Mediterranean Diet: Insights From the PREDIMED Study
  22. Does the Mediterranean diet counteract the adverse effects of abdominal adiposity?
  23. Dietary Inflammatory Index and Incidence of Cardiovascular Disease in the PREDIMED Study
  24. Nutritional adequacy according to carbohydrates and fat quality
  25. Characterization of deposits in patients with calcific tendinopathy of the supraspinatus. Role of phytate and osteopontin
  26. Effects of Polyphenols from Grape Seeds on Renal Lithiasis
  27. Extravirgin Olive Oil Consumption Reduces Risk of Atrial Fibrillation: The PREDIMED (Prevencion con Dieta Mediterranea) Trial
  28. A new device for simple and accurate urinary pH testing by the Stone-former patient
  29. Internalization of Calcium Oxalate Calculi Developed in Narrow Cavities
  30. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet
  31. Renal papillary calcification and the development of calcium oxalate monohydrate papillary renal calculi: a case series study
  32. Alcohol intake, wine consumption and the development of depression: the PREDIMED study
  33. Cálculos renales raros
  34. A simple and rapid colorimetric method for determination of phytate in urine
  35. Effects of short and long-term indapamide treatments on urinary calcium excretion in patients with calcium oxalate dihydrate urinary stone disease: A pilot study
  36. Phytotherapy in a rat model of hyperoxaluria: the antioxidant effects of quercetin involve serum paraoxonase 1 activation
  37. Urinary lithogenesis risk tests: Comparison of a commercial kit and a laboratory prototype test
  38. Urinary pH and renal lithiasis
  39. Non-infectious phosphate renal calculi: Fine structure, chemical and phase composition
  40. Rare calcium oxalate monohydrate calculus attached to the wall of the renal pelvis
  41. Study on the structure and composition of aortic valve calcific deposits. etiological aspects
  42. Effect of Tetracalcium Dimagnesium Phytate on Bone Characteristics in Ovariectomized Rats
  43. Effects of Mediterranean diets with low and high proportions of phytate-rich foods on the urinary phytate excretion
  44. A potential role for crystallization inhibitors in treatment of Alzheimer’s disease
  45. Anticalculus effect of a triclosan mouthwash containing phytate: a double-blind, randomized, three-period crossover trial
  46. Phytate in foods and significance for humans: Food sources, intake, processing, bioavailability, protective role and analysis
  47. Phytotherapy and renal stones: the role of antioxidants. A pilot study in Wistar rats
  48. Phytate inhibits bovine pericardium calcification in vitro
  49. Phytate reduces age-related cardiovascular calcification
  50. Effect of Crystallization Inhibitors on Vascular Calcifications Induced by Vitamin D
  51. Renal lithiasis and nutrition
  52. Influence of Concomitant Food Intake on the Excretion of Orally Administered myo -Inositol Hexaphosphate in Humans
  53. Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats
  54. Calcificaciones cardiovasculares: factores etiológicos implicados
  55. Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis
  56. Study of the Absorption of Myo-Inositol Hexakisphosphate (InsP6) through the Skin
  57. Absorption of myo-inositol hexakisphosphate (InsP6) through the skin: study of the matrix effects. mechanism of phytate topical absorption
  58. Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats
  59. Determination of myo-inositol hexakisphosphate (phytate) in urine by inductively coupled plasma atomic emission spectrometry
  60. Study of Potassium Phytate Effects on Decreasing Urinary Calcium in Rats
  61. Effect of phytate on element bioavailability in the second generation of rats
  62. Effects of exogenous inositol hexakisphosphate (InsP6) on the levels of InsP6 and of inositol trisphosphate (InsP3) in malignant cells, tissues and biological fluids
  63. Variation of InsP4,InsP5 and InsP6 levels in tissues and biological fluids depending on dietary phytate
  64. Phytate levels in diverse rat tissues: influence of dietary phytate
  65. Absorption and excretion of orally administered inositol hexaphosphate (IP6or phytate) in humans
  66. Dietary phytate and mineral bioavailability
  67. Urinary Phytate in Calcium Oxalate Stone Formers and Healthy People: Dietary Effects on Phytate Excretion
  68. Inositol hexakisphosphate in urine: the relationship between oral intake and urinary excretion
  69. Phytate prevents tissue calcifications in female rats
  70. Effect of atrial natriuretic peptide on α-methyl-d-glucoside intestinal active uptake in rats
  71. Changes in Intestinal Alpha-Methyl-<i>D</i>-Glucoside Uptake due to Pregnancy and Lactation in Rats
  72. Effect of cafeteria diet on intestinal absorption of palmitic acid in rats
  73. Disaccharidase activities in pregnant and lactating rats
  74. Urolithiasis and phytotherapy
  75. Effect of cafeteria diet on α-MG intestinal absorption in rats
  76. Determination of escin based on its inhibitory action on lactose crystallization
  77. Morphological Adaptive Changes of Small Intestinal Tract Regions due to Pregnancy and Lactation in Rats
  78. Effect of “Rosa Canina” Infusion and Magnesium on the Urinary Risk Factors of Calcium Oxalate Urolithiasis
  79. Dietary effects upon calcium oxalate urolithiasis risk
  80. An Animal Model to Study the Effects of Diet on Risk Factors of Calcium Stone Formation
  81. Liquid chromatographic capacity factor as an indicator of lipophilicity in a series of betablocker drugs